Multimedia Update: FDA Grants Accelerated Approval for Immunomedics’ Trodelvy in Previously-Treated Metastatic Triple-Negative Breast Cancer
23 avr. 2020 08h00 HE | Immunomedics, Inc.
First FDA-approved antibody-drug conjugate that targets the Trop-2 antigen Trodelvy is the first antibody-drug conjugate approved by FDA specifically for the treatment of relapsed or refractory...